4-硫基-1H-吡啶并[3,4-d]嘧啶 | 5334-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 4-硫基-1H-吡啶并[3,4-d]嘧啶
• 中文别名: 4-巯基吡唑并[3,4-d]嘧啶；巯异嘌呤
• 英文名称: tisopurine
• 英文别名: 8-aza-7-deaza-6-thiopurine；4-mercaptopyrazolo[3,4-d]pyrimidine；4-mercapto-1H-pyrazolo[3,4-d]-pyrimidine；1(2),5-dihydro-pyrazolo[3,4-d]pyrimidine-4-thione；1,2-dihydropyrazolo[3,4-d]pyrimidine-4-thione
• CAS: 5334-23-6
• 化学式: C₅H₄N₄S
• mdl: MFCD00005687
• 分子量: 152.18
• InChiKey: PYAOPMWCFSVFOT-UHFFFAOYSA-N

物化性质

• 熔点：
  300 °C
• 沸点：
  439.9±37.0 °C(Predicted)
• 密度：
  1.463 (estimate)
• 稳定性/保质期：
  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 储存条件：
  请将药品存放在避光、阴凉且干燥的地方，并密封保存。

SDS

Name:	4-Mercapto-1H-Pyrazolo(3 4-D)Pyrimidine Hemihydrate 99% Material Safety Data Sheet
Synonym:	1H-Pyrazolo[3,4-D]Pyrimidine-4-Thiol Hemihydrat
CAS:	5334-23-6

Section 1 - Chemical Product MSDS Name:4-Mercapto-1H-Pyrazolo(3 4-D)Pyrimidine Hemihydrate 99% Material Safety Data Sheet
Synonym:1H-Pyrazolo[3,4-D]Pyrimidine-4-Thiol Hemihydrat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5334-23-6	4-Mercapto-1H-Pyrazolo(3,4-D)Pyrimidin	99	226-251-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5334-23-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4N4S
Molecular Weight: 152.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5334-23-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Mercapto-1H-Pyrazolo(3,4-D)Pyrimidine Hemihydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5334-23-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5334-23-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5334-23-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硫基-1H-吡啶并[3,4-d]嘧啶 生成 4-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  ITINO, MOTONOBU;SATO, MASASI;KANAI, SADAMU;NAKAMURA, TOKURO

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-1H-吡唑并[3,4-d]嘧啶 在 乙醇 、 硫脲 作用下， 生成 4-硫基-1H-吡啶并[3,4-d]嘧啶
  参考文献：
  名称：

  Potential Purine Antagonists. I. Synthesis of Some 4,6-Substituted Pyrazolo [3,4-d] pyrimidines¹

  摘要：

  DOI：

  10.1021/ja01585a023

文献信息

• [EN] FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE PYRIMIDINE BICYCLIQUES FUSIONNÉES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011062885A1

  公开（公告）日：2011-05-26

  The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.

  本发明涉及融合双环嘧啶衍生物，包含融合双环嘧啶衍生物的组合物，以及利用融合双环嘧啶衍生物治疗或预防肥胖、糖尿病、代谢紊乱、心血管疾病或与患者体内G蛋白偶联受体（GPCR）活性相关的疾病的方法。
• Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones
  作者：Charles L. Cywin、Janice M. Klunder、MaryAnn Hoermann、Janice R. Brickwood、Eva David、Peter M. Grob、Racheline Schwartz、Daniel Pauletti、Kevin J. Barringer、Cheng-Kon Shih、Christopher L. Sorge、David A. Erickson、David P. Joseph、Susan E. Hattox

  DOI：10.1021/jm9707030

  日期：1998.7.1

  Nevirapine (I) is the first human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitor to reach regulatory approval. As a result of a second generation program around the tricyclic core system of nevirapine, 2-chloro-5, 11-dihydro-11-ethyl-5-methyl-8-(2-(pyridin-4-yl)ethyl)-6H-dipyrido[3, 2-b:2',3'-e][1,4]diazepin-6-one (II)1a and 2-chloro-5, 11-dihydro-11-ethyl

  奈韦拉平（I）是第一种获得监管机构批准的人类免疫缺陷病毒1型（HIV-1）非核苷逆转录酶（RT）抑制剂。作为围绕奈韦拉平三环核心系统的第二代计划的结果，2-氯-5，11-二氢-11-乙基-5-甲基-8-（2-（吡啶-4-基）乙基）-6H -dipyrido [3，2-b：2'，3'-e] [1,4]二氮杂-6-6（II）1a和2-氯-5，11-二氢-11-乙基-5-甲基-已鉴定出8-苯基乙基-6H-二吡啶并[3,2-b：2'，3'-e] [1,4]二氮杂pin-6-一（III）1a是广谱HIV-1 RT抑制剂。给出了替换II或III的8-乙基连接基的亚甲基的详细检查。已发现8-芳氧基甲基和8-芳硫基甲基是对RT的效力的优选取代方式。进一步针对一组具有临床意义的突变RT酶（K103N，V106A，G190A，P236L）以及在细胞毒性和体外代谢分析中对最有效的化合物进行了评估。最有效的化合物
• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 1. Synthesis and activity of some nucleosides of purines and 4-(alkylthio)pyrazolo[3,4-d]pyrimidines
  作者：Thomas A. Krenitsky、Janet L. Rideout、George W. Koszalka、Rosetta B. Inmon、Esther Y. Chao、Gertrude B. Elion、Victoria S. Latter、Raymond B. Williams

  DOI：10.1021/jm00343a007

  日期：1982.1

  cells than was 6. A series of 4-(alkylthio)-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidines was prepared from 4-mercapto-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine (23) and various alkyl halides. The most effective compound in this series in vivo, 4-(ethylthio)-1-beta-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine (25), cleared chicks of the parasite at 50 ppm in the diet and was much less

  发现6-（甲硫基）-9-β-D-呋喃呋喃糖基-9H-嘌呤（6）对禽球菌，艾美球虫的毒性比体外对雏鸡肝宿主细胞的毒性更大，这促使类似物的合成和测试该化合物。揭示了β-D-呋喃呋喃糖基部分是重要的结构特征，嘌呤环中的几种类型的2-取代基降低了功效，对3-脱氮基和8-氮杂环的修饰也降低了效力。相反，吡唑并6（24）的[3,4-d]嘧啶类似物活性更高。而且，该类似物对宿主细胞的毒性比6种毒性低24倍。从4种制备了一系列的4-（烷硫基）-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶-巯基-1-β-D-呋喃呋喃糖基-1H-吡唑并[3,4-d]嘧啶（23）和各种烷基卤化物。
• 4-substituted pyrazolo[3,4-d]pyrimidine derivatives
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05001127A1

  公开（公告）日：1991-03-19

  4-Substituted pyrazolo[3,4-d]pyrimidine derivatives and a method of synthesis for the derivatives are described. The 4-substituted pyrazolopyrimidine derivatives are useful as cardiotonic agents and antiarrhythmic agents.

  描述了4-取代嘧唑并[3,4-d]嘧啶衍生物以及这些衍生物的合成方法。这些4-取代嘧唑并嘧啶衍生物可用作心力衰竭药物和抗心律失常药物。

表征谱图